Tildrakizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Tildrakizumab
- Tildrakizumab: From an Undocumented Original Indication to Severe Nonproliferative Diabetic Retinopathy
Tildrakizumab: From an Undocumented Original Indication to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Tildrakizumab is an anti‑IL‑23p19 monoclonal antibody; its original approved indication and mechanism-of-action details are not yet documented in this evidence pack, and the drug is not currently marketed in Denmark. The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication or licence data in this evidence pack |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in the structured drug record. Based on the information present in this evidence pack’s repurposing rationale, Tildrakizumab is an anti‑IL‑23p19 monoclonal antibody — a class typically used to block IL‑23-driven inflammatory pathways.
Because the original indication itself is not documented here, the relationship between the (unknown) original use and diabetic retinopathy cannot be established from the available data. The evidence pack’s own rationale text is explicit that any mechanistic connection to diabetic retinopathy is indirect: it notes that the “IL‑23/Th17 axis has a speculative association with retinal microvascular disease” but characterizes this as inferential rather than direct evidence.
Given that both the mechanism-of-action field and the original indication are marked as data gaps (DG001, DG002), and no clinical or literature evidence exists to corroborate the pathway, this prediction should be treated as a hypothesis generated purely by the TxGNN model, not as a pharmacologically substantiated candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Tildrakizumab is not currently marketed in Denmark — 0 marketing authorisations (national or centralised/EMA) are on record in this evidence pack.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but this reflects model output only (Evidence Level L5) — there are zero clinical trials or publications supporting the indication, and even the mechanistic rationale is described in the evidence pack as speculative/indirect. Critical drug-level data (SmPC warnings/contraindications, mechanism of action, original indication) are also missing, which blocks any safety pre-assessment.
To proceed, the following is needed:
- SmPC/label warnings and contraindications for Tildrakizumab (DG001 — blocking)
- Confirmed mechanism of action and original approved indication (DG002)
- Preclinical or mechanistic studies directly linking IL‑23 inhibition to diabetic retinopathy pathophysiology
- Any emerging clinical trial or case-report evidence before this candidate can move beyond model-prediction stage (S0)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.